Acute myelogenous leukemia (also called acute myeloid leukemia) is a fast-growing blood cancer. It starts in the bone marrow—the “factory” inside your bones that makes blood cells. In AML, very early white blood cells (called myeloid blasts) turn cancerous. These blasts grow quickly and crowd out healthy cells. Because of this, the body cannot make enough normal red cells (you feel tired and short of breath), platelets (you bruise and bleed easily), and infection-fighting white cells (you get fevers and infections). AML can spread from the marrow into the blood and sometimes to the liver, spleen, skin, gums, or brain coverings. Doctors diagnose AML by looking at blood, bone marrow, and the genes and proteins inside the leukemia cells. Treatment aims to kill the leukemia cells, bring the disease into remission (no detectable leukemia), and keep it away (consolidation and sometimes stem cell transplant). AML is a medical emergency but many people do well with modern care.

Acute myelogenous leukemia (AML) is a fast-growing blood cancer. It starts in the bone marrow, the soft center of bones where new blood cells form. In AML, early myeloid cells (called “blasts”) grow out of control and do not mature properly. These abnormal cells fill the marrow and spill into the blood. Because they crowd out normal cells, the body cannot make enough healthy red cells (causing tiredness and paleness), platelets (causing bruising and bleeding), and infection-fighting white cells (causing fever and infections). AML can also spread to the gums, skin, brain, and other organs. Doctors diagnose AML when blast cells are high or when certain AML-defining gene changes are present. Early diagnosis and treatment are important because AML progresses quickly. Cancer.gov

Other names

AML is also known as acute myelogenous leukemia, acute myelocytic leukemia, and acute non-lymphocytic leukemia (ANLL). A special subtype with a unique gene change is acute promyelocytic leukemia (APL). Solid tumors made of AML cells outside the marrow are called myeloid sarcoma or chloroma. These names reflect older and newer terms for the same general disease family. Cancer.gov

Types

Modern systems classify AML using the leukemia’s genes plus how the cells look and behave. In 2022, two updated systems appeared: the WHO 5th edition and the International Consensus Classification (ICC). Both place strong weight on genetic findings because these predict behavior and guide care. Key ideas (in very simple terms): College of American PathologistsASH Publications+1BioMed Central

1. AML with defining genetic abnormalities
   Some gene changes “define” AML almost by themselves. Examples include fusions RUNX1-RUNX1T1 (t(8;21)), CBFB-MYH11 (inv(16)/t(16;16)), PML-RARA (APL; t(15;17)), KMT2A rearrangements, NUP98 rearrangements, MECOM (inv(3)/t(3;3)), DEK-NUP214 (t(6;9)), and BCR-ABL1. NPM1-mutated AML and certain CEBPA mutations are also defining. These labels come from the exact gene abnormality seen by molecular tests. (WHO 2022 does not require ≥20% blasts for most of these, whereas ICC usually needs ≥10% blasts; BCR-ABL1 keeps a higher blast threshold to avoid overlap with CML.) College of American Pathologists

2. AML, myelodysplasia-related (AML-MR)
   This refers to AML that arises in people with prior MDS/MDS-MPN or that carries a set of myelodysplasia-related gene mutations or cytogenetic changes (for example in ASXL1, SRSF2, U2AF1, ZRSR2, EZH2, STAG2, RUNX1, etc.). Morphology alone is no longer enough. College of American Pathologists

3. Therapy-related myeloid neoplasms
   AML that develops after prior chemotherapy or radiation is grouped as therapy-related in WHO (ICC treats “therapy-related” as a qualifier). These cases often have high-risk genetics. College of American Pathologists

4. AML with mutated TP53 (ICC category)
   ICC created a separate high-risk group when TP53 is mutated (usually with ≥20% blasts and VAF ≥10%). WHO handles TP53 differently but recognizes its poor-risk biology. PMCCollege of American Pathologists

5. AML defined by differentiation / “not otherwise specified”
   If none of the above genetic rules apply, AML is typed by which myeloid line is dominant (e.g., myeloblastic, myelomonocytic, monocytic, erythroid, megakaryoblastic). College of American Pathologists

6. Borderline “MDS/AML” (ICC)
   ICC allows an MDS/AML label when blasts are 10–19%, to support trial eligibility; WHO keeps these within MDS-IB2 but notes they may be treated as AML in practice. College of American Pathologists

Bottom line: Genetics now lead the diagnosis. Doctors use cytogenetics, FISH, and next-generation sequencing (NGS) to fit a case into the right box. College of American Pathologists

Causes and risk factors

1. Older age – AML risk rises with age because DNA changes build up in stem cells over time. Cancer.gov

2. Male sex – Men have slightly higher AML risk for reasons not fully understood. Cancer.gov

3. Smoking – Tobacco smoke contains benzene and other carcinogens that raise AML risk. American Cancer Society

4. Benzene exposure – Long-term exposure at work or from solvents increases AML risk. American Cancer Society+1

5. Prior chemotherapy – Alkylating agents and topoisomerase II inhibitors can injure marrow DNA and later lead to AML. NCBI

6. Prior radiation therapy – Ionizing radiation raises leukemia risk in a dose-related way. NCBI

7. Environmental radiation – High-level exposures (e.g., nuclear accidents) are linked to AML. Cancer.gov

8. Previous myelodysplastic syndrome (MDS) – AML may evolve from MDS. Cancer.gov

9. Previous myeloproliferative neoplasm (MPN) – Some MPNs can transform to AML over time. (General concept acknowledged in modern classifications.) College of American Pathologists

10. Clonal hematopoiesis with high-risk mutations – Age-related clones (e.g., DNMT3A, TET2, ASXL1) can progress to MDS/AML in a minority of people. (Recognized in 2022 frameworks.) College of American Pathologists

11. Down syndrome (Trisomy 21) – Strongly increases risk of myeloid leukemia in young children. Cancer.gov

12. RUNX1 familial platelet disorder – Inherited RUNX1 variants predispose to MDS/AML. ASH Publications

13. GATA2 deficiency – Germline GATA2 variants raise risk for myeloid neoplasms including AML. PMC

14. CEBPA-associated familial AML – Inherited CEBPA mutations can cause familial AML. PMC

15. DDX41 germline variants – Predispose adults (often later in life) to MDS/AML. Synapse

16. ETV6/ANKRD26 germline variants – Inherited platelet disorders with increased AML risk. PMC

17. Fanconi anemia and other DNA-repair syndromes – Marrow failure syndromes raise AML risk. PMC

18. Obesity – Several studies link excess weight with higher AML risk. (Environmental/chemical-risk syntheses include obesity among known factors.) PMC

19. Formaldehyde and certain industrial solvents – Occupational exposures have been associated with AML in some studies. PMC

20. General “inherited disorder” group – Beyond specific genes, several rare inherited conditions increase AML risk; genetic counseling is advised if family patterns suggest this. Cancer.gov

Common symptoms

1. Tiredness and weakness – From anemia when red cells are low. Cancer.gov

2. Pale skin – Another sign of anemia. Cancer.gov

3. Shortness of breath on exertion – Less oxygen-carrying capacity. Cancer.gov

4. Fever – Due to infection or the leukemia itself. Cancer.gov

5. Frequent or severe infections – White cells are abnormal and not effective. Cancer.gov

6. Easy bruising – Low platelets impair clotting. Cancer.gov

7. Bleeding gums or nosebleeds – Also from low platelets. Cancer.gov

8. Petechiae (tiny red spots) – Small skin bleeds from capillaries. Cancer.gov

9. Bone or joint pain – Marrow packed with blasts increases pressure. Cancer.gov

10. Loss of appetite and weight loss – A general cancer effect. Cancer.gov

11. Night sweats – A common systemic symptom. Cancer.gov

12. Swollen gums (gingival overgrowth) – Especially in monocytic forms. Cancer.gov

13. Fullness under left ribs – Enlarged spleen from blood cell buildup. Cancer.gov

14. Headache, dizziness, confusion, or vision changes – Can occur with very high white counts (leukostasis) or CNS involvement. Cancer.gov

15. Skin lumps or greenish masses (chloromas) – Myeloid sarcoma deposits under the skin or in tissues. Cancer.gov

Diagnostic tests

(Grouped as Physical Exam, Manual Tests, Lab/Pathology, Electrodiagnostic, Imaging. Each item explains what it shows and why it matters.)

Physical exam

1. General exam and vital signs – Doctors look for fever, fast heart rate, fast breathing, and overall illness. This sets urgency and guides immediate care for infection or bleeding. Cancer.gov

2. Skin and mucosa check – Petechiae, purpura, bruises, and gum bleeding suggest low platelets and possible clotting problems. Cancer.gov

3. Mouth and gum exam – Swollen, tender gums can signal monocytic AML and heavy leukemic cell load in tissues. Cancer.gov

4. Abdominal exam for liver and spleen size – Enlargement points to blood cell buildup or leukemia cell collections. Cancer.gov

5. Neurologic and eye (fundus) exam – Headache, confusion, or retinal hemorrhages can reflect leukostasis or bleeding in severe cases. Cancer.gov

Manual tests

6. Peripheral blood smear with manual differential – A technologist reviews a stained slide by eye to spot blasts, Auer rods, and abnormal shapes. This quick, low-tech step strongly supports the diagnosis. Cancer.gov

7. Cytochemical stains on cells (e.g., myeloperoxidase, Sudan Black B, non-specific esterase) – Simple dye reactions help show if blasts are myeloid or monocytic when flow cytometry is not immediately available. Cancer.gov

8. Manual blast count on bone-marrow smears – Counting blasts across several fields gives a blast percentage, a core part of the diagnostic criteria before genetic results return. Cancer.gov

Laboratory & pathological tests

9. Complete blood count (CBC) – Measures numbers of red cells, white cells, and platelets and flags blasts or severe cytopenias. Cancer.gov

10. Peripheral blood smear (laboratory readout) – Confirms blasts, looks for Auer rods, and helps rule out other causes of cytopenias. Cancer.gov

11. Bone marrow aspiration and core biopsy – Obtains marrow cells and a tiny core of bone to examine under the microscope; this is the central test for AML. Cancer.gov

12. Flow cytometry immunophenotyping – Uses fluorescent antibodies and light detection to define the leukemia’s “surface marker” pattern (e.g., CD13, CD33, CD117, HLA-DR, monocytic markers). This confirms lineage and subtype. Cancer.gov

13. Conventional cytogenetics (karyotyping) – Looks at the chromosomes for translocations, inversions, or extra/missing material that define AML types and risk. Cancer.gov

14. FISH (fluorescence in situ hybridization) – A targeted way to detect key fusions (such as PML-RARA, RUNX1-RUNX1T1, CBFB-MYH11) even if the karyotype looks normal. Cancer.gov

15. Molecular testing (PCR/NGS panels) – Finds gene mutations that classify AML (e.g., NPM1, FLT3, IDH1/2, TP53, ASXL1) and guide therapy and prognosis. Modern classifications and ELN 2022 stress broad, accurate molecular testing at diagnosis. ASH PublicationsCollege of American Pathologists

16. Coagulation panel (PT/INR, aPTT, fibrinogen, D-dimer) – Screens for disseminated intravascular coagulation (DIC), especially in acute promyelocytic leukemia, and helps manage bleeding risk. Cancer.gov

Electrodiagnostic tests

17. 12-lead ECG (electrocardiogram) – Checks heart rhythm and conduction. It is useful at diagnosis to detect effects of fever, anemia, or electrolyte problems and to set a baseline before cardiotoxic drugs. Guidelines in cardio-oncology recommend baseline cardiac testing when anthracyclines are planned. Portail Vasculaire

18. EEG (electroencephalogram) when seizures or encephalopathy are present – If a patient has seizures or altered consciousness, EEG helps assess brain function while other tests look for bleeding, infection, or leukemic infiltration. (Used selectively, not routinely.) Cancer.gov

Imaging tests

19. CT scan (targeted to symptoms; e.g., head/abdomen) – CT can check for bleeding in the brain, infections, organ enlargement, or solid tumor deposits of AML (myeloid sarcoma). It is commonly used after diagnosis to see whether leukemia has spread outside the marrow. Cancer.gov

20. Lumbar puncture with CSF testing (and imaging guidance if needed) – This is a procedure rather than an image, but it evaluates the central nervous system. Doctors may do it if there are neurologic symptoms or in higher-risk subtypes to see if AML has reached the spinal fluid. Cancer.gov

Non-Pharmacological Treatments

Physiotherapy

1. Energy conservation training
   Description (≈150 words): A therapist teaches you how to spread your activities across the day, take planned rests, and simplify tasks (sitting to shower, using stools in the kitchen, batching chores). You learn to prioritize what matters most and to stop before exhaustion hits.
   Purpose: Reduce cancer-related fatigue during chemo.
   Mechanism: Balances limited energy with daily demands; prevents “boom-and-bust.”
   Benefits: Less fatigue, steadier function, improved mood and independence.

2. Graded walking program
   Description: Short, frequent walks (even 3–5 minutes) around the room or hallway, gradually extended as counts and stamina allow.
   Purpose: Maintain heart-lung fitness and prevent deconditioning.
   Mechanism: Gentle aerobic activity enhances oxygen use and mitochondrial efficiency.
   Benefits: Better endurance, sleep, and appetite; reduces thromboembolism risk.

3. Breathing exercises (diaphragmatic + pacing)
   Description: Slow belly breathing with longer exhales; match breath to steps or movements.
   Purpose: Ease breathlessness and anxiety; support stamina.
   Mechanism: Activates the parasympathetic system, reduces heart rate, improves ventilation.
   Benefits: Calmer mood, lower perceived effort, improved exercise tolerance.

4. Gentle resistance training (bands/light weights)
   Description: Very low-load, high-control sets for major muscle groups, adjusted to blood counts and symptoms.
   Purpose: Preserve muscle mass and strength during treatment.
   Mechanism: Stimulates muscle protein synthesis.
   Benefits: Easier transfers, stair climbing, and self-care; less sarcopenia.

5. Range-of-motion mobility
   Description: Daily joint and soft-tissue movements for shoulders, hips, spine, ankles.
   Purpose: Prevent stiffness from bed time or central line guarding.
   Mechanism: Lubricates joints, maintains tendon glide.
   Benefits: Less pain, better posture, safer gait.

6. Balance and fall-prevention drills
   Description: Static and dynamic balance (feet together, semi-tandem), safe turns, and home safety review.
   Purpose: Reduce fall risk during anemia, orthostatic symptoms, or neuropathy.
   Mechanism: Trains proprioception and protective stepping.
   Benefits: Fewer injuries and hospital delays.

7. Posture and spinal care
   Description: Seated alignment, scapular setting, and gentle back extensors.
   Purpose: Prevent musculoskeletal pain from prolonged bed or chair time.
   Mechanism: Optimizes biomechanics and muscle balance.
   Benefits: Less neck/shoulder tightness, easier breathing.

8. Peripheral neuropathy management (if present)
   Description: Sensory re-education, foot checks, shoe advice, and safety drills.
   Purpose: Limit injury from numbness/tingling caused by some drugs.
   Mechanism: Compensatory strategies and protective behaviors.
   Benefits: Safer walking, fewer skin injuries.

9. Lymphatic and edema-aware movement
   Description: Gentle limb movements with elevation; avoid tight garments and heavy lifting when platelets are low.
   Purpose: Manage swelling and comfort.
   Mechanism: Muscle pump supports lymph/venous return.
   Benefits: Less heaviness, better range.

10. Paced activities of daily living (ADLs)
    Description: Break hygiene, dressing, and meal prep into steps with rests.
    Purpose: Keep independence during treatment dips.
    Mechanism: Prevents anaerobic overexertion.
    Benefits: Confidence and dignity.

11. Orthostatic symptom management
    Description: Ankling/pumping before standing; slow transitions; compression per team advice.
    Purpose: Reduce dizziness and fainting.
    Mechanism: Improves venous return and autonomic adaptation.
    Benefits: Safer transfers, fewer falls.

12. Bed mobility & pressure-relief positions
    Description: Log-rolling, pillow placement, and 2-hourly pressure relief.
    Purpose: Prevent pressure injuries.
    Mechanism: Reduces continuous pressure on skin.
    Benefits: Skin integrity, comfort.

13. Gentle yoga-informed mobility (no inversion, line-safe)
    Description: Chair-based stretches and mindful movement, approved by the team.
    Purpose: Ease stiffness and anxiety.
    Mechanism: Combines flexibility with parasympathetic tone.
    Benefits: Relaxation, better sleep.

14. In-room mini-circuits
    Description: Short sequences (sit-to-stand, heel raises, wall push-ups) tailored to counts.
    Purpose: Keep whole-body function when outdoor activity is limited.
    Mechanism: Brief, frequent muscle activation.
    Benefits: Strength and morale.

15. Discharge/home program & caregiver training
    Description: Simple written plan with safety rules and red-flag checklist.
    Purpose: Smooth transition from hospital to home.
    Mechanism: Retention through repetition and demonstration.
    Benefits: Fewer readmissions; safer home routine.

Mind-Body & “Gene-by-Lifestyle” Support

16. Mindfulness-based stress reduction (MBSR)
    Description: Guided attention training (breath, body scan) 10–20 minutes/day.
    Purpose: Lower stress, improve sleep and mood.
    Mechanism: Calms HPA axis and inflammation pathways; may influence gene expression linked to stress.
    Benefits: Better coping, pain tolerance, and quality of life.

17. Coping-skills counseling (CBT-style)
    Description: Brief, structured sessions to reframe worries and plan actions.
    Purpose: Reduce anxiety/depression; improve adherence.
    Mechanism: Replaces catastrophic thoughts with problem-solving.
    Benefits: More control, less distress.

18. Relaxation training (progressive muscle relaxation/guided imagery)
    Description: Tension-release cycles with soothing mental pictures.
    Purpose: Ease nausea, pain, and insomnia.
    Mechanism: Parasympathetic activation and attention shift.
    Benefits: Comfort, calmer heart rate.

19. Meaning-centered or spiritual care
    Description: Explore values, purpose, and sources of strength with trained staff.
    Purpose: Reduce existential distress.
    Mechanism: Enhances resilience and hope pathways.
    Benefits: Peace, motivation for self-care.

20. Sleep hygiene program
    Description: Fixed wake time, light exposure by day, quiet/dark at night, limit naps to 20–30 minutes.
    Purpose: Restore sleep quality disrupted by steroids, chemo, or hospital routines.
    Mechanism: Re-anchors circadian rhythm.
    Benefits: Energy, mood, cognition.

Educational Therapy

21. Neutropenia & infection-prevention coaching
    Description: Hand hygiene, mask use in clinics, safe food handling, pet/lawn precautions.
    Purpose: Cut infection risk when counts are low.
    Mechanism: Blocks exposure and translocation.
    Benefits: Fewer infections and delays.

22. Bleeding-risk education
    Description: Platelet-safe life tips: soft toothbrush, electric razor, no contact sports, stool softeners to avoid straining.
    Purpose: Prevent bleeding when platelets are low.
    Mechanism: Avoids trauma and pressure.
    Benefits: Less bruising/bleeding.

23. Central-line care teaching
    Description: Keep site dry/clean, watch for redness, fevers; know when to call.
    Purpose: Prevent catheter infections/clots.
    Mechanism: Asepsis and early action.
    Benefits: Safer therapy access.

24. Medication & interaction literacy
    Description: Simple med list, timing chart, and interaction “watch-outs” (antifungals with FLT3 or venetoclax, herbals).
    Purpose: Improve adherence and safety.
    Mechanism: Memory aids and hazard awareness.
    Benefits: Fewer errors, better outcomes.

25. Fertility, work, and financial navigation
    Description: Early referral for fertility options (time-sensitive), work accommodations, and aid programs.
    Purpose: Protect life plans and reduce stress.
    Mechanism: Informed choices, resource linkage.
    Benefits: Lower distress, practical support.

---

Drug Treatments

Safety note: AML drugs can cause severe low counts, infections, bleeding, organ toxicity, heart rhythm changes, and tumor lysis. All dosing/timing is clinician-directed.

1. Cytarabine (Ara-C) — Antimetabolite
   Dosage/Time: Induction (part of “7+3”): 100–200 mg/m²/day by continuous IV for 7 days. High-dose consolidation: 1.5–3 g/m² IV every 12 h on days 1, 3, 5 (cycles vary).
   Purpose/Mechanism: Blocks DNA synthesis in blasts.
   Side effects: Low counts, fever, mucositis, liver enzyme rise; high-dose can cause cerebellar toxicity and eye irritation (steroid eye drops may be used).

2. Daunorubicin — Anthracycline
   Dosage/Time: 60–90 mg/m² IV daily on days 1–3 with cytarabine (7+3).
   Purpose/Mechanism: Intercalates DNA, inhibits topoisomerase II.
   Side effects: Low counts, nausea, hair loss; cardiomyopathy risk (lifetime dose limits), infusion reactions.

3. Idarubicin — Anthracycline
   Dosage/Time: 12 mg/m² IV days 1–3 (often used instead of daunorubicin).
   Purpose/Mechanism: Similar to daunorubicin; sometimes better marrow penetration.
   Side effects: As above; cardiac monitoring required.

4. Mitoxantrone — Anthracenedione
   Dosage/Time: 10–12 mg/m² IV days 1–3 in some regimens or salvage.
   Purpose/Mechanism: DNA intercalation/topoisomerase II inhibition.
   Side effects: Myelosuppression, mucositis, cardiac toxicity risk.

5. CPX-351 (liposomal daunorubicin + cytarabine)
   Dosage/Time: Induction: liposomal formulation delivering daunorubicin 44 mg/m² + cytarabine 100 mg/m² IV on days 1, 3, 5; consolidation days 1 & 3.
   Purpose/Mechanism: Fixed 1:5 molar ratio in liposomes targets blasts—especially therapy-related AML or AML with MDS-changes.
   Side effects: Prolonged neutropenia, infections, mucositis; monitor heart function.

6. Azacitidine — Hypomethylating agent (HMA)
   Dosage/Time: 75 mg/m² SC/IV days 1–7 of 28-day cycles (alternative 5-2-2 schedule).
   Purpose/Mechanism: Epigenetic “unmasks” genes, pushing blasts toward maturation; used in older/unfit or with venetoclax.
   Side effects: Low counts, GI upset, injection reactions.

7. Decitabine — HMA
   Dosage/Time: 20 mg/m² IV days 1–5 of 28-day cycles.
   Purpose/Mechanism: Similar to azacitidine.
   Side effects: Myelosuppression, fatigue, infections.

8. Venetoclax — BCL-2 inhibitor
   Dosage/Time: Ramp up to 400 mg PO daily; combined with azacitidine (75 mg/m² d1–7) or decitabine (20 mg/m² d1–5).
   Purpose/Mechanism: Triggers apoptosis in AML blasts.
   Side effects: Tumor lysis syndrome, low counts, infections; strong CYP3A4 interactions (many azoles require dose reduction).

9. Midostaurin — FLT3 inhibitor
   Dosage/Time: 50 mg PO twice daily on days 8–21 with 7+3 for newly diagnosed FLT3-mutated AML; may continue with later cycles.
   Purpose/Mechanism: Blocks FLT3 signaling.
   Side effects: Nausea, QT prolongation, rash; drug interactions.

10. Gilteritinib — FLT3 inhibitor
    Dosage/Time: 120 mg PO daily for relapsed/refractory FLT3-mutated AML.
    Purpose/Mechanism: Inhibits FLT3-ITD/TKD.
    Side effects: Liver enzyme rise, differentiation-like syndrome, QT prolongation.

11. Quizartinib — FLT3-ITD inhibitor
    Dosage/Time: Dosing varies by protocol (commonly ~35–60 mg PO daily) in combination/maintenance for newly diagnosed FLT3-ITD AML per local approval.
    Purpose/Mechanism: Selective FLT3-ITD blockade.
    Side effects: QT prolongation, myelosuppression; ECG monitoring.

12. Enasidenib — IDH2 inhibitor
    Dosage/Time: 100 mg PO daily.
    Purpose/Mechanism: Reverses 2-HG oncometabolite, enabling differentiation.
    Side effects: Differentiation syndrome, bilirubin rise (UGT1A1), edema.

13. Ivosidenib — IDH1 inhibitor
    Dosage/Time: 500 mg PO daily.
    Purpose/Mechanism: Similar to enasidenib for IDH1-mutated AML.
    Side effects: Differentiation syndrome, QT prolongation.

14. Gemtuzumab ozogamicin — Anti-CD33 antibody-drug conjugate
    Dosage/Time: Commonly 3 mg/m² IV (max 4.5 mg) on specified days with induction/consolidation per protocol.
    Purpose/Mechanism: Delivers calicheamicin toxin into CD33+ blasts.
    Side effects: Liver injury (VOD/SOS risk), myelosuppression, fever.

15. APL-specific therapy (subtype of AML): ATRA + Arsenic Trioxide
    Dosage/Time: ATRA 45 mg/m²/day PO in 2 doses; ATO 0.15 mg/kg IV daily during induction/consolidation.
    Purpose/Mechanism: Forces promyelocytes to mature.
    Side effects: Differentiation syndrome, QT prolongation (ATO), headaches, liver enzyme rise.
    Note: This applies to acute promyelocytic leukemia (APL), a special AML subtype; emergency treatment is life-saving.

---

Dietary “Molecular” Supplements

Important: Evidence for supplements in AML is limited. Some antioxidants or herbals can interfere with chemotherapy or increase bleeding/infection risk. Food-first, safe-food-handling nutrition is the priority.

1. Vitamin D (if deficient)
   Dose: As prescribed after a blood test (often 800–2000 IU/day maintenance; loading if very low).
   Function/Mechanism: Supports bone, muscle, and immune modulation.
   Notes: Monitor levels; avoid high doses without labs.

2. Omega-3 fatty acids (EPA/DHA)
   Dose: Often 1–2 g/day combined EPA+DHA with food (if platelets stable and no bleeding issues).
   Function: May aid inflammation balance, appetite, and weight maintenance.
   Caution: Small antiplatelet effect—check with team.

3. Oral nutrition shakes (protein + calories)
   Dose: 1–2 servings/day as needed.
   Function: Meet energy/protein needs when appetite is poor.
   Mechanism: Provides complete macronutrients and micronutrients.

4. Glutamine (for mucositis—evidence mixed)
   Dose: Protocol-guided (often divided doses totaling ~10–30 g/day).
   Function: Fuel for gut cells; may help mouth sores.
   Caution: Only if your center uses it.

5. Psyllium or soluble fiber
   Dose: 1 tsp in water 1–2×/day as tolerated.
   Function: Smooths stool consistency (diarrhea/constipation).
   Caution: Hydrate well; avoid during severe neutropenia if GI symptoms flare.

6. Ginger capsules
   Dose: 500–1000 mg/day split doses.
   Function: Helps nausea.
   Caution: Possible antiplatelet effect—clear with team.

7. Melatonin (sleep aid)
   Dose: 1–3 mg at bedtime.
   Function: Supports sleep and circadian rhythm.
   Note: Check interactions if on sedatives.

8. L-carnitine (fatigue—mixed data)
   Dose: ~1–2 g/day if approved.
   Function: Mitochondrial energy support.
   Caution: GI upset possible.

9. Standard multivitamin within RDA
   Dose: 1 daily without high-dose antioxidants.
   Function: Cover micronutrient gaps.
   Caution: Avoid “mega-dose” products.

10. Electrolyte solutions (oral rehydration)
    Dose: Sips through the day when dehydrated.
    Function: Replace fluids/salts, protect kidneys during therapy.
    Note: Watch sugar if diabetic.

(Deliberately not recommending probiotics, turmeric/curcumin, or high-dose antioxidants unless your oncologist explicitly approves, because of infection/interaction concerns.)

---

Immunity/Regenerative/Stem-Cell-Related” Therapies

1. Filgrastim (G-CSF)
   Dose: Commonly 5 mcg/kg/day SC, timing varies (often after chemo until count recovery).
   Function/Mechanism: Stimulates neutrophil production to shorten neutropenia.
   Notes: Bone pain; rare spleen issues.

2. Pegfilgrastim (long-acting G-CSF)
   Dose: 6 mg SC once per cycle (given per protocol).
   Function: Same as G-CSF with single shot.
   Notes: Bone pain; avoid too close to chemo start.

3. Sargramostim (GM-CSF)
   Dose: ~250 mcg/m²/day SC/IV per protocol.
   Function: Broad myeloid stimulation.
   Notes: Fever, injection reactions.

4. Intravenous immunoglobulin (IVIG) (select cases)
   Dose: Weight-based, intermittent.
   Function: Temporary antibody support if severe hypogammaglobulinemia/recurrent infections.
   Notes: Headache, thrombosis risk, expensive; used selectively.

5. Plerixafor (CXCR4 inhibitor—mobilization)
   Dose: 0.24 mg/kg SC for stem cell mobilization (mainly autologous settings).
   Function: Mobilizes stem cells into blood for collection.
   Note: AML usually uses allogeneic transplant; mobilization applies to donors/other contexts.

6. Hematopoietic Stem Cell Transplant (HSCT) “medications”
   Explanation: HSCT is a procedure, but it relies on conditioning drugs (e.g., busulfan, cyclophosphamide, fludarabine) and immunosuppression (e.g., tacrolimus, methotrexate).
   Function: Replace diseased marrow with healthy donor stem cells; provide a graft-versus-leukemia effect.
   Notes: Major risks (infections, graft-versus-host disease). Decision is highly individualized.

---

 Procedures/“Surgeries” in AML

1. Central venous catheter (port/PICC) placement
   Procedure: Minor surgical insertion for long-term IV access.
   Why: Safe chemo, blood draws, transfusions.

2. Leukapheresis
   Procedure: Machine removes excess white cells from blood.
   Why: Emergency control of hyperleukocytosis to reduce stroke/lung risk while chemo begins.

3. Bone marrow biopsy/aspirate
   Procedure: Needle sampling of hip bone marrow.
   Why: Diagnose AML, check remission status, study genetics.

4. Lumbar puncture ± intrathecal chemo
   Procedure: Needle into lower back to sample or treat CSF.
   Why: Evaluate/treat CNS involvement or prophylaxis in selected cases.

5. Allogeneic hematopoietic stem cell transplant
   Procedure: High-risk, potentially curative therapy using donor stem cells.
   Why: Best long-term control for selected patients based on risk genetics/response.

---

Prevention & Safety Tips

1. Hand hygiene and masks in clinics.

2. Safe food handling; avoid raw/undercooked meats, unpasteurized dairy, and raw sprouts.

3. Prompt fever plan: ≥38.0 °C (100.4 °F) = urgent call/ER.

4. Oral care: soft brush, saline/bicarbonate rinses; avoid alcohol mouthwashes.

5. Bleeding safety with low platelets: no contact sports; electric razor; stool softeners.

6. Medication list with interaction checks; avoid unapproved supplements/herbals.

7. Vaccines: inactivated only when team approves; household gets up-to-date vaccines.

8. Sun protection (some drugs increase sensitivity).

9. Movement daily within limits; avoid prolonged bed rest.

10. Keep a “red-flag” card and emergency contacts with you.

---

When to See a Doctor Urgently

• Fever ≥38.0 °C (100.4 °F) or chills

• Bleeding that doesn’t stop, black/tarry stool, or new severe bruises

• Chest pain, shortness of breath, confusion, severe headache, stroke-like symptoms

• Painful mouth sores with trouble drinking or peeing very little (dehydration)

• Catheter redness, pus, swelling, or new severe pain

• Sudden swelling of legs, new calf pain, or one-sided weakness

• Fast weight gain, swelling, or breathing issues during ATRA/IDH therapy (possible differentiation syndrome)

• Any medication error or suspected overdose

---

What to Eat” and “What to Avoid

Eat/Choose:

1. Well-cooked proteins (eggs, chicken, fish, legumes).

2. Pasteurized dairy/yogurt (if approved), cheese from pasteurized milk.

3. Well-washed/cooked vegetables and peeled fruits.

4. Whole grains and soft foods when mouth is sore (oatmeal, soups).

5. Small, frequent, high-protein snacks; oral nutrition shakes.

Avoid (especially during neutropenia):

1. Raw/undercooked meats, sushi, raw sprouts.
2. Unpasteurized dairy/juices; soft cheeses made from unpasteurized milk.
3. Salad bars/buffets and foods sitting out at room temperature.
4. Herbal/mega-antioxidant supplements not cleared by oncology (may interact).
5. Alcohol to excess; grapefruit products if your meds have CYP3A warnings.

---

Frequently Asked Questions

1. Is AML curable?
   Yes. Many people reach remission; some are cured, especially with transplant or targeted therapy when indicated.

2. How fast must treatment start?
   Often within days of diagnosis; APL subtype needs same-day ATRA.

3. What is “7+3”?
   7 days of cytarabine + 3 days of an anthracycline (like daunorubicin) for induction.

4. Will I need a transplant?
   Depends on your leukemia genetics, age/fitness, and response. Your team uses risk scores to decide.

5. How are genetics used?
   Mutations (FLT3, NPM1, IDH1/2, etc.) guide prognosis and targeted drugs.

6. Can I work during treatment?
   Sometimes part-time or remote. Fatigue and infection risk are common. Plan with your employer.

7. What about fertility?
   Discuss options before therapy when possible; referral is time-sensitive.

8. How long is treatment?
   Induction is weeks; consolidation or transplant follows. HMA/venetoclax regimens are monthly cycles.

9. What is differentiation syndrome?
   A sudden inflammatory reaction with targeted drugs (ATRA/ATO, IDH inhibitors). It needs urgent steroids and monitoring.

10. How do I prevent infections?
    Hand hygiene, masks in clinics, safe food, avoid sick contacts, and call for fever.

11. Can I take vitamins or herbs?
    Only if your oncology team approves. Some interact dangerously with chemo/targeted drugs.

12. Why are blood/platelet transfusions needed?
    To treat anemia and reduce bleeding during low counts.

13. What is MRD?
    Minimal residual disease—very sensitive tests that detect tiny amounts of leukemia after treatment.

14. How is pain managed?
    By treating the cause, using safe pain medicines, mouth-sore care, and gentle movement.

15. What helps fatigue?
    Treat anemia/infection, pace activities, short walks, rest, nutrition, and sleep routines.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 07, 2025.